Form 6-K XORTX Therapeutics Inc. For: Sep 10
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number: 001-40858
XORTX Therapeutics Inc.
3710 – 33rd Street NW, Calgary, Alberta, Canada T2L 2M1
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
EXHIBIT INDEX
| Exhibit | Description | |
| 99.1 | News release dated September 10, 2026. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| XORTX Therapeutics Inc. | |||
| Date: September 10, 2026 | By: | /s/ Allen Davidoff | |
| Name: | Allen Davidoff | ||
| Title: | Co-Chief Executive Officer | ||
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- XRP Price Prediction: XRP Could Rally Another 60%, but Could AlphaPepe Turn a Smaller Entry Into a Bigger Opportunity?
- J2 Flooring Highlights Total Cost of Ownership in Commercial Flooring Decisions
- Cindi Love Announces Opportunity Architects Framework to Redesign Leadership and Learning in the Age of AI
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
